Assessment of Docetaxel- and Paclitaxel-Related Diffuse Parenchymal Lung Disease: Two Case Reports

Previous studies have reported the development of hypersensitivity pneumonia, interstitial pneumonia and organized pneumonia, two parenchymal lung diseases that are clinically and radiologically interchangeable, secondary to docetaxel and paclitaxel (Taxane) use. Parenchymal lung diseases secondary to docetaxel treatment are rare, but may have serious and even fatal consequences, and any delay in diagnosis and treatment can result in a poor prognosis. Docetaxel treatment should be discontinued and corticosteroid therapy should be initiated as soon as lung involvement becomes a concern. We present here two different cases who developed diffuse parenchymal lung toxicity associated with Taxane use, considering the information in literature.